CoChat
Sign Up
Cited by 46Immunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment

Open access
Zhou, Hong, Ma, Yipeng, Liu, Fenglan, Li, Bin, Qiao, Dongjuan, Ren, Peigen, Wang, Mingjun·2023·Frontiers in Immunology
DOI 10.3389/fimmu.2023.1255799PMC PMC10508181
Open this paper in CoChat — free accountOpen PDF

Abstract

New York-esophageal cancer 1 (NY-ESO-1) belongs to the cancer testis antigen (CTA) family, and has been identified as one of the most immunogenic tumor-associated antigens (TAAs) among the family members. Given its ability to trigger spontaneous humoral and cellular immune response and restricted expression, NY-ESO-1 has emerged as one of the most promising targets for cancer immunotherapy. Cancer vaccines, an important element of cancer immunotherapy, function by presenting an exogenous source of TAA proteins, peptides, and antigenic epitopes to CD4 + T cells via major histocompatibility complex class II (MHC-II) and to CD8 + T cells via major histocompatibility complex class I (MHC-I). These mechanisms further enhance the immune response against TAAs mediated by cytotoxic T lymphocytes (CTLs) and helper T cells. NY-ESO-1-based cancer vaccines have a history of nearly two decades, starting from the first clinical trial conducted in 2003. The current cancer vaccines targeting NY-ESO-1 have various types, including Dendritic cells (DC)-based vaccines, peptide vaccines, protein vaccines, viral vaccines, bacterial vaccines, therapeutic whole-tumor cell vaccines, DNA vaccines and mRNA vaccines, which exhibit their respective benefits and obstacles in the development and application. Here, we summarized the current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment, aiming to provide perspectives for future research.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2023.1255799

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Together, these studies identify well-defined candidates for first-in-human evaluation.

    “Together, these studies identify well-defined candidates for first-in-human evaluation while underscoring the need to address translational barriers related to scalability, regulatory approval, and patient stratification.”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [82]

    The Conclusion and perspectives (page unavailable) says that promising preclinical results have led to new clinical trials, supporting the general idea of candidates for human evaluation. It does not identify specific, well-defined candidates awaiting first-in-human evaluation; the trial table lists numerous NY-ESO-1 vaccines already studied in humans. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

  • M13 phages presenting NY-ESO-1 activated dendritic cells and primed CD8+ T cells, resulting in enhanced antitumor activity.

    “Similarly, M13 phages presenting the cancer-testis antigen New York esophageal squamous cell carcinoma 1 (NY-ESO-1) activated dendritic cells and primed CD8+ T cells, resulting in enhanced antitumor activity [82,83]”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [82]

    The DC vaccines section describes NY-ESO-1-loaded dendritic cells and T-cell responses, while the Viral vaccines section discusses other vaccine vectors. Searches for “M13” and “phage display” found no passage reporting that NY-ESO-1-presenting M13 phages activated dendritic cells, primed CD8+ T cells, or enhanced antitumor activity. Page numbers were unavailable in our copy. (LLM, conf=0.74)

    Experimental — accuracy not yet measured

  • Engineered phage vaccines displaying tumor-associated antigens or delivering immunostimulatory cargo have demonstrated robust antitumor immunity and survival benefits in multiple mouse models.

    “In parallel, engineered phage vaccines displaying tumor-associated antigens or delivering immunostimulatory cargo have demonstrated robust antitumor immunity and survival benefits in multiple mouse models [80–85]”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [82]

    The Bacterial vaccines section discusses engineered Salmonella delivering NY-ESO-1 in mice, while the Viral vaccines section discusses fowlpox and vaccinia vectors. Searches for phage vaccines, bacteriophages, and mouse survival benefits found no passage addressing the claimed phage-vaccine results. (LLM, conf=0.74)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 75

  1. [1]Chen YT Boyer AD Viars CS Tsang S Old LJ Arden KC. Genomic cloning and localization of ctag, a gene encoding an autoimmunogenic cancer-testis antigen ny-eso-1, to human chromosome xq28. Cytogenet Cell Genet (1997) 79(3-4): 237–40. doi: 10.1159/000134734 9605863 · DOI
  2. [2]Gnjatic S Nishikawa H Jungbluth AA Gure AO Ritter G Jager E. Ny-eso-1: review of an immunogenic tumor antigen. Adv Cancer Res (2006) 95: 1– 30. doi: 10.1016/S0065-230X(06)95001-5 16860654 · DOI
  3. [3]Thomas R Al-Khadairi G Roelands J Hendrickx W Dermime S Bedognetti D. Ny-eso-1 based immunotherapy of cancer: current perspectives. Front Immunol (2018) 9: 947. doi: 10.3389/fimmu.2018.00947 29770138 PMC5941317 · DOI
  4. [4]Hemminger JA Ewart Toland A Scharschmidt TJ Mayerson JL Kraybill WG Guttridge DC. The cancer-testis antigen ny-eso-1 is highly expressed in myxoid and round cell subset of liposarcomas. Mod Pathol (2013) 26(2): 282–8. doi: 10.1038/modpathol.2012.133 22936067 · DOI
  5. [5]Pollack SM Jungbluth AA Hoch BL Farrar EA Bleakley M Schneider DJ. Ny-eso-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer (2012) 118(18): 4564–70. doi: 10.1002/cncr.27446 PMC3361576 22359263 · DOI
  6. [6]Jungbluth AA Antonescu CR Busam KJ Iversen K Kolb D Coplan K. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen ny-eso-1 but not mage-A1 or ct7. Int J Cancer (2001) 94(2): 252–6. doi: 10.1002/ijc.1451 11668506 · DOI
  7. [7]Odunsi K Jungbluth AA Stockert E Qian F Gnjatic S Tammela J. Ny-eso-1 and lage-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res (2003) 63(18): 6076–83. 14522938
  8. [8]Rodolfo M Luksch R Stockert E Chen YT Collini P Ranzani T. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of ny-eso-1 tumor antigen. Cancer Res (2003) 63(20): 6948–55. 14583496
  9. [9]Barrow C Browning J MacGregor D Davis ID Sturrock S Jungbluth AA. Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res (2006) 12(3 Pt 1): 764–71. doi: 10.1158/1078-0432.CCR-05-1544 16467087 · DOI
  10. [10]Chehelgerdi M Chehelgerdi M. The use of rna-based treatments in the field of cancer immunotherapy. Mol Cancer (2023) 22(1): 106. doi: 10.1186/s12943-023-01807-w 37420174 PMC10401791 · DOI
  11. [11]Saxena M van der Burg SH Melief CJM Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer (2021) 21(6): 360–78. doi: 10.1038/s41568-021-00346-0 33907315 · DOI · Paper page
  12. [12]Lin MJ Svensson-Arvelund J Lubitz GS Marabelle A Melero I Brown BD. Cancer vaccines: the next immunotherapy frontier. Nat Cancer (2022) 3(8): 911–26. doi: 10.1038/s43018-022-00418-6 35999309 · DOI
  13. [13]Kantoff PW Higano CS Shore ND Berger ER Small EJ Penson DF. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 363(5): 411–22. doi: 10.1056/NEJMoa1001294 20818862 · DOI · Paper page
  14. [14]Sharma P Hu-Lieskovan S Wargo JA Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell (2017) 168(4): 707–23. doi: 10.1016/j.cell.2017.01.017 PMC5391692 28187290 · DOI · Paper page
  15. [15]Wang S He Z Wang X Li H Liu XS. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction. Elife (2019) 8: e49020. doi: 10.7554/eLife.49020 31767055 PMC6879305 · DOI
  16. [16]da Silva AJ Zangirolami TC Novo-Mansur MT Giordano Rde C Martins EA. Live bacterial vaccine vectors: an overview. Braz J Microbiol (2014) 45(4): 1117–29. doi: 10.1590/s1517-83822014000400001 PMC4323283 25763014 · DOI
  17. [17]Janeway CA Jr. Medzhitov R. Innate immune recognition. Annu Rev Immunol (2002) 20: 197– 216. doi: 10.1146/annurev.immunol.20.083001.084359 11861602 · DOI · Paper page
  18. [18]Nishikawa H Sato E Briones G Chen LM Matsuo M Nagata Y. In vivo antigen delivery by a salmonella typhimurium type iii secretion system for therapeutic cancer vaccines. J Clin Invest (2006) 116(7): 1946–54. doi: 10.1172/JCI28045 PMC1481660 16794737 · DOI
  19. [19]Nishikawa H Tsuji T Jager E Briones G Ritter G Old LJ. Induction of regulatory T cell-resistant helper cd4+ T cells by bacterial vector. Blood (2008) 111(3): 1404–12. doi: 10.1182/blood-2007-09-113761 17986662 · DOI
  20. [20]Shata MT Stevceva L Agwale S Lewis GK Hone DM. Recent advances with recombinant bacterial vaccine vectors. Mol Med Today (2000) 6(2): 66– 71. doi: 10.1016/s1357-4310(99)01633-0 10652479 · DOI
  21. [21]Banchereau J Steinman RM. Dendritic cells and the control of immunity. Nature (1998) 392(6673): 245–52. doi: 10.1038/32588 9521319 · DOI
  22. [22]Figdor CG de Vries IJ Lesterhuis WJ Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 10(5): 475–80. doi: 10.1038/nm1039 15122249 · DOI
  23. [23]Palucka K Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity (2013) 39(1): 38– 48. doi: 10.1016/j.immuni.2013.07.004 23890062 PMC3788678 · DOI · Paper page
  24. [24]Bol KF Figdor CG Aarntzen EH Welzen ME van Rossum MM Blokx WA. Intranodal vaccination with mrna-optimized dendritic cells in metastatic melanoma patients. Oncoimmunology (2015) 4(8): e1019197. doi: 10.1080/2162402X.2015.1019197 26405571 PMC4570143 · DOI
  25. [25]Gilboa E. Dc-based cancer vaccines. J Clin Invest (2007) 117(5): 1195–203. doi: 10.1172/JCI31205 PMC1857263 17476349 · DOI
  26. [26]Gilboa E Vieweg J. Cancer immunotherapy with mrna-transfected dendritic cells. Immunol Rev (2004) 199: 251–63. doi: 10.1111/j.0105-2896.2004.00139.x 15233739 · DOI
  27. [27]Schuler G Schuler-Thurner B Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol (2003) 15(2): 138–47. doi: 10.1016/s0952-7915(03)00015-3 12633662 · DOI
  28. [28]Van Tendeloo VF Ponsaerts P Lardon F Nijs G Lenjou M Van Broeckhoven C. Highly efficient gene delivery by mrna electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mrna and to electroporation of plasmid cdna for tumor antigen loading of dendritic cells. Blood (2001) 98(1): 49– 56. doi: 10.1182/blood.v98.1.49 11418462 · DOI · Paper page
  29. [29]Westdorp H Creemers JHA van Oort IM Schreibelt G Gorris MAJ Mehra N. Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer. J Immunother Cancer (2019) 7(1): 302. doi: 10.1186/s40425-019-0787-6 31727154 PMC6854814 · DOI
  30. [30]Frankiw L Singh A Peters C Comin-Anduix B Berent-Maoz B Macabali M. Immunotherapy resistance driven by loss of ny-eso-1 expression in response to transgenic adoptive cellular therapy with pd-1 blockade. J Immunother Cancer (2023) 11(5): e006930. doi: 10.1136/jitc-2023-006930 37156551 PMC10173990 · DOI
  31. [31]Chawla SP Van Tine BA Pollack SM Ganjoo KN Elias AD Riedel RF. Phase ii randomized study of cmb305 and atezolizumab compared with atezolizumab alone in soft-tissue sarcomas expressing ny-eso-1. J Clin Oncol (2022) 40(12): 1291–300. doi: 10.1200/JCO.20.03452 34260265 · DOI
  32. [32]Pollack SM Lu H Gnjatic S Somaiah N O’Malley RB Jones RL. First-in-human treatment with a dendritic cell-targeting lentiviral vector-expressing ny-eso-1, lv305, induces deep, durable response in refractory metastatic synovial sarcoma patient. J Immunother (2017) 40(8): 302–6. doi: 10.1097/CJI.0000000000000183 PMC5733794 28891906 · DOI
  33. [33]Gnjatic S Altorki NK Tang DN Tu SM Kundra V Ritter G. Ny-eso-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res (2009) 15(6): 2130–9. doi: 10.1158/1078-0432.CCR-08-2632 PMC5806520 19276258 · DOI
  34. [34]Xue W Metheringham RL Brentville VA Gunn B Symonds P Yagita H. Scib2, an antibody DNA vaccine encoding ny-eso-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade. Oncoimmunology (2016) 5(6): e1169353. doi: 10.1080/2162402X.2016.1169353 27471648 PMC4938367 · DOI
  35. [35]Wei J Hui AM. The paradigm shift in treatment from covid-19 to oncology with mrna vaccines. Cancer Treat Rev (2022) 107: 102405. doi: 10.1016/j.ctrv.2022.102405 35576777 PMC9068246 · DOI · Paper page
  36. [36]Lorentzen CL Haanen JB Met O Svane IM. Clinical advances and ongoing trials on mrna vaccines for cancer treatment. Lancet Oncol (2022) 23(10): e450–e8. doi: 10.1016/S1470-2045(22)00372-2 PMC9512276 36174631 · DOI
  37. [37]Lang F Schrors B Lower M Tureci O Sahin U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat Rev Drug Discovery (2022) 21(4): 261–82. doi: 10.1038/s41573-021-00387-y PMC7612664 35105974 · DOI
  38. [39]Conry RM LoBuglio AF Wright M Sumerel L Pike MJ Johanning F. Characterization of a messenger rna polynucleotide vaccine vector. Cancer Res (1995) 55(7): 1397–400. doi: 10.1007/BF01519900 7882341 · DOI
  39. [42]Papachristofilou A Hipp MM Klinkhardt U Fruh M Sebastian M Weiss C. Phase ib evaluation of a self-adjuvanted protamine formulated mrna-based active cancer immunotherapy, bi1361849 (Cv9202), combined with local radiation treatment in patients with stage iv non-small cell lung cancer. J Immunother Cancer (2019) 7(1): 38. doi: 10.1186/s40425-019-0520-5 30736848 PMC6368815 · DOI
  40. [43]Sebastian M Papachristofilou A Weiss C Fruh M Cathomas R Hilbe W. Phase ib study evaluating a self-adjuvanted mrna cancer vaccine (Rnactive(R)) combined with local radiation as consolidation and maintenance treatment for patients with stage iv non-small cell lung cancer. BMC Cancer (2014) 14: 748. doi: 10.1186/1471-2407-14-748 25288198 PMC4195907 · DOI
  41. [44]Bezu L Kepp O Cerrato G Pol J Fucikova J Spisek R. Trial watch: peptide-based vaccines in anticancer therapy. Oncoimmunology (2018) 7(12): e1511506. doi: 10.1080/2162402X.2018.1511506 30524907 PMC6279318 · DOI
  42. [45]Tang M Cai JH Diao HY Guo WM Yang X Xing S. The progress of peptide vaccine clinical trials in gynecologic oncology. Hum Vaccin Immunother (2022) 18(5): 2062982. doi: 10.1080/21645515.2022.2062982 35687860 PMC9450897 · DOI
  43. [46]Ordaz ML Larmonier N Lybarger L. Dc-Expressed Mhc Class I Single-Chain Trimer-Based Vaccines Prime Cytotoxic T Lymphocytes against Exogenous but Not Endogenous Antigens. Cell Immunol (2010) 262(2): 141–9. doi: 10.1016/j.cellimm.2010.02.006 20199770 · DOI
  44. [47]Ebert LM MacRaild SE Zanker D Davis ID Cebon J Chen W. A cancer vaccine induces expansion of ny-eso-1-specific regulatory T cells in patients with advanced melanoma. PloS One (2012) 7(10): e48424. doi: 10.1371/journal.pone.0048424 23110239 PMC3482213 · DOI
  45. [48]Nicholaou T Ebert LM Davis ID McArthur GA Jackson H Dimopoulos N. Regulatory T-cell-mediated attenuation of T-cell responses to the ny-eso-1 iscomatrix vaccine in patients with advanced Malignant melanoma. Clin Cancer Res (2009) 15(6): 2166–73. doi: 10.1158/1078-0432.CCR-08-2484 19276262 · DOI
  46. [49]Davis ID Chen W Jackson H Parente P Shackleton M Hopkins W. Recombinant ny-eso-1 protein with iscomatrix adjuvant induces broad integrated antibody and cd4(+) and cd8(+) T cell responses in humans. Proc Natl Acad Sci U.S.A. (2004) 101(29): 10697–702. doi: 10.1073/pnas.0403572101 PMC489997 15252201 · DOI
  47. [50]Patel BK Wang C Lorens B Levine AD Steinmetz NF Shukla S. Cowpea mosaic virus (Cpmv)-based cancer testis antigen ny-eso-1 vaccine elicits an antigen-specific cytotoxic T cell response. ACS Appl Bio Mater (2020) 3(7): 4179–87. doi: 10.1021/acsabm.0c00259 PMC8340627 34368641 · DOI
  48. [51]Apostolico Jde S Lunardelli VA Coirada FC Boscardin SB Rosa DS. Adjuvants: classification, modus operandi, and licensing. J Immunol Res (2016) 2016: 1459394. doi: 10.1155/2016/1459394 27274998 PMC4870346 · DOI
  49. [52]Ishikawa T Kageyama S Miyahara Y Okayama T Kokura S Wang L. Safety and antibody immune response of chp-ny-eso-1 vaccine combined with poly-iclc in advanced or recurrent esophageal cancer patients. Cancer Immunol Immunother (2021) 70(11): 3081–91. doi: 10.1007/s00262-021-02892-w PMC10991152 33751208 · DOI
  50. [53]Pavlick A Blazquez AB Meseck M Lattanzi M Ott PA Marron TU. Combined vaccination with ny-eso-1 protein, poly-iclc, and montanide improves humoral and cellular immune responses in patients with high-risk melanoma. Cancer Immunol Res (2020) 8(1): 70– 80. doi: 10.1158/2326-6066.CIR-19-0545 31699709 PMC6946846 · DOI
  51. [54]Takeoka T Nagase H Kurose K Ohue Y Yamasaki M Takiguchi S. Ny-eso-1 protein cancer vaccine with poly-iclc and ok-432: rapid and strong induction of ny-eso-1-specific immune responses by poly-iclc. J Immunother (2017) 40(4): 140–7. doi: 10.1097/CJI.0000000000000162 28338507 · DOI
  52. [55]Tsuji T Sabbatini P Jungbluth AA Ritter E Pan L Ritter G. Effect of montanide and poly-iclc adjuvant on human self/tumor antigen-specific cd4+ T cells in phase I overlapping long peptide vaccine trial. Cancer Immunol Res (2013) 1(5): 340–50. doi: 10.1158/2326-6066.CIR-13-0089 24777970 · DOI
  53. [56]Adams S O’Neill DW Nonaka D Hardin E Chiriboga L Siu K. Immunization of Malignant melanoma patients with full-length ny-eso-1 protein using tlr7 agonist imiquimod as vaccine adjuvant. J Immunol (2008) 181(1): 776–84. doi: 10.4049/jimmunol.181.1.776 PMC2583094 18566444 · DOI
  54. [57]Ishihara M Tono Y Miyahara Y Muraoka D Harada N Kageyama S. First-in-human phase I clinical trial of the ny-eso-1 protein cancer vaccine with nod2 and tlr9 stimulants in patients with ny-eso-1-expressing refractory solid tumors. Cancer Immunol Immunother (2020) 69(4): 663–75. doi: 10.1007/s00262-020-02483-1 PMC7113205 31980914 · DOI
  55. [58]Kakimi K Isobe M Uenaka A Wada H Sato E Doki Y. A phase I study of vaccination with ny-eso-1f peptide mixed with picibanil ok-432 and montanide isa-51 in patients with cancers expressing the ny-eso-1 antigen. Int J Cancer (2011) 129(12): 2836–46. doi: 10.1002/ijc.25955 21448901 · DOI
  56. [59]Valmori D Souleimanian NE Tosello V Bhardwaj N Adams S O’Neill D. Vaccination with ny-eso-1 protein and cpg in montanide induces integrated antibody/th1 responses and cd8 T cells through cross-priming. Proc Natl Acad Sci U.S.A. (2007) 104(21): 8947–52. doi: 10.1073/pnas.0703395104 PMC1885608 17517626 · DOI
  57. [60]Karbach J Gnjatic S Bender A Neumann A Weidmann E Yuan J. Tumor-reactive cd8+ T-cell responses after vaccination with ny-eso-1 peptide, cpg 7909 and montanide isa-51: association with survival. Int J Cancer (2010) 126(4): 909–18. doi: 10.1002/ijc.24850 19728336 · DOI
  58. [61]Diefenbach CS Gnjatic S Sabbatini P Aghajanian C Hensley ML Spriggs DR. Safety and immunogenicity study of ny-eso-1b peptide and montanide isa-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res (2008) 14(9): 2740–8. doi: 10.1158/1078-0432.CCR-07-4619 18451240 · DOI
  59. [62]Karbach J Neumann A Atmaca A Wahle C Brand K von Boehmer L. Efficient in vivo priming by vaccination with recombinant ny-eso-1 protein and cpg in antigen naive prostate cancer patients. Clin Cancer Res (2011) 17(4): 861–70. doi: 10.1158/1078-0432.CCR-10-1811 21163871 · DOI
  60. [63]Patel SP Petroni GR Roszik J Olson WC Wages NA Chianese-Bullock KA. Phase I/ii trial of a long peptide vaccine (Lpv7) plus toll-like receptor (Tlr) agonists with or without incomplete freund’s adjuvant (Ifa) for resected high-risk melanoma. J Immunother Cancer (2021) 9(8): e003220. doi: 10.1136/jitc-2021-003220 34413169 PMC8378357 · DOI
  61. [64]Legat A Maby-El Hajjami H Baumgaertner P Cagnon L Abed Maillard S Geldhof C. Vaccination with lag-3ig (Imp321) and peptides induces specific cd4 and cd8 T-cell responses in metastatic melanoma patients–report of a phase I/iia clinical trial. Clin Cancer Res (2016) 22(6): 1330–40. doi: 10.1158/1078-0432.CCR-15-1212 26500235 · DOI
  62. [65]Baumgaertner P Costa Nunes C Cachot A Maby-El Hajjami H Cagnon L Braun M. Vaccination of stage iii/iv melanoma patients with long ny-eso-1 peptide and cpg-B elicits robust cd8(+) and cd4(+) T-cell responses with multiple specificities including a novel dr7-restricted epitope. Oncoimmunology (2016) 5(10): e1216290. doi: 10.1080/2162402X.2016.1216290 27853637 PMC5087303 · DOI
  63. [66]Kageyama S Wada H Muro K Niwa Y Ueda S Miyata H. Dose-dependent effects of ny-eso-1 protein vaccine complexed with cholesteryl pullulan (Chp-ny-eso-1) on immune responses and survival benefits of esophageal cancer patients. J Transl Med (2013) 11: 246. doi: 10.1186/1479-5876-11-246 24093426 PMC4015172 · DOI
  64. [67]Sabbatini P Tsuji T Ferran L Ritter E Sedrak C Tuballes K. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-iclc shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res (2012) 18(23): 6497–508. doi: 10.1158/1078-0432.CCR-12-2189 23032745 · DOI
  65. [68]Klein O Davis ID McArthur GA Chen L Haydon A Parente P. Low-dose cyclophosphamide enhances antigen-specific cd4(+) T cell responses to ny-eso-1/iscomatrix vaccine in patients with advanced melanoma. Cancer Immunol Immunother (2015) 64(4): 507–18. doi: 10.1007/s00262-015-1656-x PMC11029160 25662405 · DOI
  66. [70]Le Gal FA Ayyoub M Dutoit V Widmer V Jager E Cerottini JC. Distinct structural tcr repertoires in naturally occurring versus vaccine-induced cd8+ T-cell responses to the tumor-specific antigen ny-eso-1. J Immunother (2005) 28(3): 252–7. doi: 10.1097/01.cji.0000161398.34701.26 15838382 · DOI
  67. [71]Xu L Zheng J Nguyen DH Luong QT Zeng G. Enhancing whole-tumor cell vaccination by engaging innate immune system through ny-eso-1/dendritic cell interactions. J Immunother (2013) 36(8): 412–22. doi: 10.1097/CJI.0b013e3182a80263 23994888 · DOI
  68. [72]Jager E Karbach J Gnjatic S Neumann A Bender A Valmori D. Recombinant vaccinia/fowlpox ny-eso-1 vaccines induce both humoral and cellular ny-eso-1-specific immune responses in cancer patients. Proc Natl Acad Sci U.S.A. (2006) 103(39): 14453–8. doi: 10.1073/pnas.0606512103 PMC1570182 16984998 · DOI
  69. [73]Odunsi K Matsuzaki J Karbach J Neumann A Mhawech-Fauceglia P Miller A. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing ny-eso-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U.S.A. (2012) 109(15): 5797–802. doi: 10.1073/pnas.1117208109 PMC3326498 22454499 · DOI
  70. [74]Vogel TU Visan L Ljutic B Gajewska B Caterini J Salha D. Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother (2010) 33(8): 743–58. doi: 10.1097/CJI.0b013e3181eccc87 20842062 · DOI
  71. [75]von Boehmer L Mattle M Bode P Landshammer A Schafer C Nuber N. Ny-eso-1-specific immunological pressure and escape in a patient with metastatic melanoma. Cancer Immun (2013) 13: 12. 23882157 PMC3718732
  72. [76]van der Burg SH Arens R Ossendorp F van Hall T Melief CJ. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer (2016) 16(4): 219–33. doi: 10.1038/nrc.2016.16 26965076 · DOI
  73. [77]Ma L Dichwalkar T Chang JYH Cossette B Garafola D Zhang AQ. Enhanced Car-T Cell Activity against Solid Tumors by Vaccine Boosting through the Chimeric Receptor. Science (2019) 365(6449): 162–8. doi: 10.1126/science.aav8692 PMC6800571 31296767 · DOI
  74. [78]Ma L Hostetler A Morgan DM Maiorino L Sulkaj I Whittaker CA. Vaccine-boosted car T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell (2023) 186(15): 3148–65. doi: 10.1016/j.cell.2023.06.002 PMC10372881 37413990 · DOI
  75. [79]Drakes DJ Abbas AM Shields J Steinbuck MP Jakubowski A Seenappa LM. Lymph node-targeted vaccine boosting of tcr-T cell therapy enhances anti-tumor function and eradicates solid tumors. bioRxiv (2022). doi: 10.1101/2022.05.05.490779 PMC10835214 38270373 · DOI

Cited by

Sorted by citations

Authors
Zhou, H., Ma, Y., Liu, F., Li, B., Qiao, D., Ren, P., & Wang, M.
Affiliations
Chinese Academy of Sciences (CN)
Corresponding author
Wang, Mingjun
ORCID
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2023-09-05
Volume
14
Pages
1255799-1255799
ISSN
1664-3224 (ISSN-L)
DOI
10.3389/fimmu.2023.1255799
PMC
PMC10508181
OpenAlex
W4386441113
Cited by
46
References
4
Citations by year
2026: 14 · 2025: 18 · 2024: 12 · 2023: 2
FWCI
1.28
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Basic and Applied Basic Research Foundation of Guangdong Province (2020B1515120018)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
NY-ESO-1, cancer vaccines, cancer-testis antigens, tumor-associated antigens, cancer immunotherapy, dendritic cell vaccine, peptide vaccine, DNA vaccine, mRNA vaccines, whole tumor cell vaccine, viral vaccines, bacterial vaccines, MHC presentation, cytotoxic T lymphocytes, solid tumors
MeSH terms
Antibodies, Bacterial Vaccines, Humans, Immunotherapy, Male, Neoplasms, CD8-Positive T-Lymphocytes, Cancer Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review